We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure

By MedImaging International staff writers
Posted on 02 May 2024
Print article
Image: The multi-spectral optoacoustic tomography (MSOT) machine generates images of biological tissues (Photo courtesy of University of Missouri)
Image: The multi-spectral optoacoustic tomography (MSOT) machine generates images of biological tissues (Photo courtesy of University of Missouri)

Imaging inflammation using traditional radiological techniques presents significant challenges, including radiation exposure, poor image quality, high costs, and invasive procedures. Now, new contrast agents and imaging technology are being developed to improve the monitoring of inflammatory disorders like inflammatory bowel disease, arthritis, hepatitis, and other autoimmune diseases.

A team of researchers at the University of Missouri (Columbia, MO, USA) is developing new methods to track the progression of inflammatory disorders using cutting-edge imaging technologies. They are developing the first probiotic bacterial-based contrast agent suitable for use with multispectral optoacoustic tomography (MSOT). This novel contrast agent incorporates lactic acid bacteria that produce a distinctive glowing blue color in MSOT imaging. MSOT itself is a non-radiative imaging technology that offers high-resolution images of biological tissues using light and sound, similar to an ultrasound procedure. This advancement marks a significant leap in creating bacterial-based, optoacoustic detectable contrast agents for the diagnosis and management of inflammation.

“Because this non-invasive technique does not require exposure to radiation it is possible to more regularly obtain imaging from patients to monitor disease progression and response to therapy,” said Jorge Gomez-Gutierrez, PhD, an associate professor of pediatrics at the University of Missouri School of Medicine who is leading the research team. “Unlike the synthetic contrast agents currently available, the natural agent we are developing is less expensive to produce and doesn’t offer the downsides of the synthetic agents, which can aggravate a patient’s IBD or colitis.”

Related Links:
University of Missouri

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Endoscopic Ultrasound Fine Needle Biopsy Device
Acquire
New
Ultrasound System
Voluson Signature 18
New
Compact C-Arm
Arcovis DRF-C S21

Print article

Channels

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.